| Process | 2017 (Criteria C) | 2018 (UDST) |
| Number of presumptive TB cases tested | 68,735 | 71,438 |
| Number (%) found to be smear positive | 7386 (10.7) | 7648 (10.7) |
| Number (%) of patients who were loss to follow-up before and during first line anti-TB treatment | 566 (7.6) | 345 (4.5) |
| Number (%) of patients who died before and during first line anti-TB treatment | 634 (8.5) | 604 (7.8) |
| Number (%) eligible for DR-TB testing | 2440 (33) | 7648 (100) |
| Number (%) tested for DR-TB | 2440 (100) | 5129 (67) |
| Number found to be H + R resistant | 80 (3.3) | 154 (3.0) |
| Number found to be H-mono resistant |
| 82 (1.5) |
| Number found to be XDR |
| 22 (0.4) |
| Number (%) of patients with any resistance | 80 (3.27) | 258 (5.03)* |
| Number (%) of patients who died before DR-TB treatment initiation | 8 (10) | 11 (4.2) |
| Number (%) of patients who were LFU before DR-TB treatment initiation | 8 (10) | 15 (1) |